The XIAP inhibitor Embelin enhances TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 769-777

  Hu, Rong ^a   Yang, Ying ^a   Liu, Zhuogang ^a   Jiang, Huinan ^a   Zhu, Ke ^a   Li, Jia ^a   Xu, Wenhui ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Death receptor; Leukemia; TRAIL; XIAP

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; EMBELIN; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BENZOQUINONE DERIVATIVE; CASPASE; TNFRSF10A PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE SILENCING; GENETIC TRANSFECTION; HL 60 CELL LINE; HUMAN; HUMAN CELL; LEUKEMIA; MTT ASSAY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TRANSCRIPTION INITIATION;

APOPTOSIS; BENZOQUINONES; CASPASES; CELL PROLIFERATION; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; LEUKEMIA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTIONAL ACTIVATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84925484228     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2702-6     Document Type: Article

References (25)

1. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16:1701–8.
2. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D, et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem. 2003;278:5444–54.
3. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol. 2004;4:333–9.
4. Oldenhuis CN, Stegehuis JH, Walenkamp AM, de Jong S, de Vries EG. Targeting TRAIL death receptors. Curr Opin Pharmacol. 2008;8(4):433–9.
5. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363–7.
6. Di X, Zhang G, Zhang Y, Takeda K, Rosado LA, Zhang B. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget. 2013;4(9):1349–64.
7. Morizot A, Mérino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, et al. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ. 2011;18(4):700–11.
8. Lemke J, von Karstedt S, Abd El Hay M, Conti A, Arce F, Montinaro A, et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ. 2014;21(3):491–502.
9. Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol Cancer Ther. 2012;11(7):1518–27.
10. Ahn KS, Sethi G, Aggarwal BB. Embelin, an inhibitor of X chromosome-linked inhibitor-of- apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic geneproducts. Mol Pharmacol. 2007;71:209–19.
11. Hu R, Zhu K, Li Y, Yao K, Zhang R, Wang H, et al. Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells. Med Oncol. 2011;28:1584–8.
12. Lee YJ, Seol JW, Jeong JK, Moon MH, Park SY. Inhibition of the ubiquitin-proteasome system sensitizes TRAIL-resistant prostate cancer cells by up-regulation of death receptor 5. Mol Med Rep. 2011;4:1255–9.
13. Vaculova A, Kaminskyy V, Jalalvand E, Surova O, Zhivotovsky B. Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Mol Cancer. 2010;9:87.
14. Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail AC, et al. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Investig. 2011;29:511–20.
15. Su L, Liu G, Hao X, Zhong N, Zhong D, Liu X, et al. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur J Cancer. 2011;47:2471–8.
16. Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, et al. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res. 2007;142(2):281–6.
17. Jiang L, Hao JL, Jin ML, Zhang YG, Wei P. Effect of Embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells. Asian Pac J Cancer Prev. 2013;14(10):6115–20.
18. Matte I, Lane D, Boivin M, Rancourt C, Piché A. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer. 2014;14(1):234.
19. Siegelin MD, Gaiser T, Siegelin Y. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int. 2009;55(6):423–30.
20. Liu X, Yue P, Khuri FR, Sun SY. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res. 2005;65(20):9169–75.
21. Cheng J, Hylander BL, Baer MR, Chen X, Repasky EA. Multiple mechanism underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther. 2006;5:1844–53.
22. Hersey P, Zhang XD. Overcoming resistance of cancer cells to apoptosis. J Cell Physiol. 2003;196:9–18.
23. Wu B, Wang X, Chi ZF, Hu R, Zhang R, Yang W, et al. Ursolic acid-induced apoptosis in K562 cells involving upregulation of PTEN gene expression and inactivation of the PI3K/Akt pathway. Arch Pharm Res. 2012;35:543–8.
24. Wang S, El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A. 2003;100:15095–100.
25. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, et al. C-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 2004;64:7570–8.